CPSC Staff (2012) — CPSIA §101(b) Functional Purpose Exception: Public-Health-Protection Criterion

A 26-page U.S. Consumer Product Safety Commission staff report dated November 2012, bearing the standard CPSC staff caveat that “these comments are those of the CPSC staff and have not been reviewed or approved by, and may not necessarily reflect the views of, the Commission.” The report addresses the third of three statutory criteria the Commission must find to grant a functional-purpose exception from the CPSIA Section 101(a) 100 ppm total-lead content limit for children’s products: that the exception “will have no measurable adverse effect on public health or safety,” where the Public Law 112-28 amendment to §101(b) defines “no measurable adverse effect” as “no measurable increase in blood lead levels of a child.” Staff derive a quantitative interpretation: a measurable BLL increase is approximately 0.8 µg/dL, and the daily exposure to lead from a children’s product that would produce that BLL increase is approximately 2.2 µg/day. The report contains no primary lead-occurrence measurements; it is a methodology and threshold-derivation document built from published BLL biokinetic modelling (EPA IEUBK), the Lanphear et al. (2005) international pooled BLL–IQ dose-response analysis, the Parsons et al. (2001) interlaboratory BLL-reference-material analysis, and the OEHHA (2007) child-specific benchmark BLL-change framework, and includes a January–March 2012 external scientific peer review by five reviewers with staff responses.

Key numbers

• Statutory phased substrate-lead reduction (p. 1): the Consumer Product Safety Improvement Act of 2008 (CPSIA) §101(a) set 600 ppm lead in children’s products effective February 10, 2009, then 300 ppm effective August 14, 2009, then 100 ppm effective August 14, 2011 unless the Commission determines that limit is not technologically feasible. The Commission did not so determine, so the 100 ppm limit binds children’s products manufactured after August 14, 2011 except where the §101(b) exception applies.
• Three §101(b) statutory exception criteria, as amended by Public Law 112-28 (p. 1; Appendix A p. A-1, quoting 15 USC §1278a(b)(1)(A)): the Commission may grant an exception only if it finds (i) the product, class of product, material, or component part requires the inclusion of lead because it is not practicable or technologically feasible to manufacture it by removing the lead or making the lead inaccessible; (ii) the product or part is not likely to be placed in the mouth or ingested, taking into account normal and reasonably foreseeable use and abuse by a child; and (iii) the exception will have no measurable adverse effect on public health or safety. Subparagraph (B) defines “no measurable adverse effect” as “no measurable increase in blood lead levels of a child.”
• Reference national BLL distribution in children ages 1–5 (p. 3, CDC NHANES 2007–2008 via CDC 2012): median (50th percentile) 1.4 µg/dL; 95th percentile 4.1 µg/dL. Geometric-mean BLL for U.S. children ages 1–5 is reported as approximately 1.5 µg/dL in footnote 4 (citing CDC 2012). Historical trend, cited to CDC 2009: during 1988–1994, 4.4 % of children ages 1–5 had BLL ≥10 µg/dL; during 1999–2004, that fraction had fallen to 1.4 % (p. 3, CDC 2009 citation).
• Lanphear et al. (2005) pooled BLL–IQ dose-response model (p. 3 with citation to Environ Health Perspect 113:894–899): the international pooled analysis of children with BLLs in the 2.4–30 µg/dL range fits a log-linear model with adjustment for covariates of the form Change in IQ = ln(BLL) × (−2.7). The 95 % confidence interval on the coefficient is (−3.74, −1.66). The model is non-linear: incremental IQ loss per 1 µg/dL BLL increase is larger at lower BLLs (BLLs <7.5 µg/dL or <10 µg/dL produce a steeper slope than BLLs already in the higher range).
• IQ loss over BLL 1 → 10 µg/dL (p. 4): point estimate 6.2 IQ points total over the 1–10 µg/dL BLL range, equivalent to an average of 0.69 IQ points per 1 µg/dL BLL increase. Using the upper bound of the 95 % CI on the coefficient (−3.74), the same 1 → 10 µg/dL change predicts a loss of 8.6 IQ points (average 0.96 IQ points per 1 µg/dL BLL increase). Using the lower bound (−1.66): 3.8 IQ points total (average 0.42 per 1 µg/dL). For children’s-products evaluation, staff selected the upper bound of the 95 % CI (−3.74; 0.96 IQ points per 1 µg/dL) as the more health-protective option (p. 4).
• Parsons et al. (2001) interlaboratory BLL reference-material certifications (p. 7, citing Spectrochim Acta Part B 56:1593–1604): four blood-lead reference materials, analysed by eight referee laboratories in the New York State proficiency-testing programme using three different analytical methods across nine datasets, were certified at all-method means ± between-laboratory SDs of 5.9 ± 0.4 µg/dL, 14.5 ± 0.6 µg/dL, 42.2 ± 1.8 µg/dL, and 76.0 ± 2.2 µg/dL. Staff applied the ±0.4 µg/dL between-laboratory standard deviation from the lowest-concentration reference (5.9 µg/dL sample) as the practical estimate of measurement precision at BLLs comparable to those in current U.S. children.
• Definition of “measurable increase in BLL” (p. 8, p. 12): approximately two times the standard deviation of the lowest-BLL reference material ≈ 0.8 µg/dL. Staff explicitly compare this 0.8 µg/dL threshold to the OEHHA (2007) child-specific benchmark BLL change of 1 µg/dL and to the OEHHA-stated correspondence “1 µg/dL increase in BLL ≈ 1 IQ point loss.” Staff note that the de minimus language in OEHHA (2007) (“changes in blood lead less than the adopted [1 µg/dL change] are expected to cause no measurable adverse effect”) is the same statutory phrasing used in CPSIA §101(b)(1)(A)(iii) and that “this may not be coincidental.”
• CDC 42 CFR §493.937 clinical-laboratory performance criteria for BLL proficiency testing (p. 6): acceptable error for BLL is ±4 µg/dL or ±10 %, whichever is greater for samples within the clinically relevant range of values (1 µg/dL to >80 µg/dL; up to 40 µg/dL the allowance is ±4 µg/dL, above 40 µg/dL the allowance is ±10 % of target). The CDC Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP, November 16–18, 2010 meeting) voted unanimously to recommend tightening the criterion to ±2 µg/dL or ±10 %, whichever is greater.
• IEUBK biokinetic-model derivation of the 2.2 µg/day exposure threshold (p. 9): using the EPA Integrated Exposure Uptake BioKinetic Model for Lead in Children (Windows version IEUBKwin v1.1 build 11, February 2010, 32-bit), staff ran the model with all default inputs (default geometric standard deviation GSD = 1.6; default absorption 50 % for diet and water, 30 % for soil and dust) for the 0–84-month age range. The default-input geometric mean BLL is 2.730 µg/dL with a calculated 95th percentile of 5.915 µg/dL. Adding a hypothetical additional daily lead exposure of 2.2 µg/day (using a 50 % absorption assumption for the lead-containing children’s product, chosen as the more health-protective default rather than the 30 % soil-and-dust default) produces a geometric mean of 3.088 µg/dL with a 95th percentile of 6.690 µg/dL — i.e., a 95th-percentile BLL shift of approximately 0.8 µg/dL, the operational definition of a measurable BLL increase. Hence staff identify 2.2 µg/day as the daily-exposure threshold below which exception products will not result in a measurable BLL increase.
• IQ-loss equivalent of an 0.8 µg/dL BLL increase (p. 9–10): approximately 0.6 IQ points using the 0.69 IQ-points-per-1 µg/dL central estimate, or approximately 0.8 IQ points using the 0.96 IQ-points-per-1 µg/dL upper-bound estimate. Staff frame both as below the OEHHA (2007) de minimus criterion (1 IQ point) and the EPA (2008) NAAQS-framework value (2 IQ points; 73 FR 67000, 67005), and conclude (p. 11) that this level of population-average IQ change “would not be observable in an individual.”
• Lead-particle-inhalation route considered and bounded (p. 13): staff conclude that exposure to lead through inhalation of particles released into the air during normal use of children’s products is uncommon because (i) lead and lead compounds used in consumer products are not volatile and (ii) significant releases of lead-containing particles from products into the air are not expected for most products. Inhalation must nonetheless be assessed case-by-case in any exception petition.
• §101(b) staff recommendation (p. 13): the statutory condition that an exception “will have no measurable adverse effect on public health or safety” is met if a child’s potential exposure to lead from the excepted product is estimated to result in an increase in BLL of less than 0.8 µg/dL, corresponding to a daily exposure of approximately 2.2 µg/day. Staff specify that exception evaluations should rest on estimated normal and reasonably foreseeable use and abuse, including (a) wipe-sampling to estimate transfer of lead from the product surface to the child’s hands and then to the mouth, and (b) case-by-case assessment of any inhalation of lead-containing particles. Staff explicitly acknowledge these conclusions are subject to change as new information becomes available.
• Bicycle / motor sports / tractor-toy precedent (p. 13): staff note that for previously submitted exclusion petitions (bicycles, motor sports equipment, brass parts on a tractor toy), the actual estimated lead exposure from the potentially excepted products was considerably less than the 2.2 µg/day threshold; nonetheless, exposure must be assessed product-by-product.
• External peer review (Appendix B, p. B-1 to B-9): in January 2012 CPSC staff sought external scientific peer review of the draft report; comments from five reviewers were received in March 2012; staff revised the report based on the comments. The appendix tabulates 26 named comments with staff responses, including reviewer concerns about (i) population-versus-individual framing of IQ effects, (ii) the non-linear concentration–response curve at low BLLs, (iii) sensitivity-subgroup protection, (iv) the OEHHA de minimus statutory language, and (v) the appropriateness of the IEUBK model inputs (mean intake, GSD, averaging time).

Methods (brief)

This is a regulatory-derivation document, not an analytical-chemistry study. The report has no field sampling, no laboratory analysis of primary samples, and no primary measurement of lead. Its methodology consists of: (i) selecting a quantitative definition of “measurable increase in BLL” from published interlaboratory-validation data on certified reference materials (Parsons et al. 2001 mean ± between-laboratory SD at the lowest reference concentration); (ii) applying the published Lanphear et al. (2005) log-linear BLL–IQ dose-response model to convert the BLL increase into an IQ-loss estimate, using the upper bound of the 95 % confidence interval on the coefficient as the health-protective option; (iii) running the EPA IEUBK biokinetic model for children aged 0–84 months at default inputs (GSD = 1.6, 50 % absorption for product-derived lead, 30 % for soil/dust) to identify the daily incremental exposure that shifts the modelled 95th-percentile BLL by the measurable-increase threshold; and (iv) cross-comparing the resulting IQ-loss estimate against the OEHHA (2007) child-specific benchmark BLL change (1 µg/dL ≈ 1 IQ point) and the EPA (2008) NAAQS framework for lead (which treated up to a 2-point IQ loss as the basis for the air-quality standard). External peer review of the draft was conducted in January–March 2012 by five reviewers (charges and itemised comment-response tables appear in Appendix B). The methodology is documentary and biokinetic-modelling-based; reproducibility depends on the cited published inputs (CDC NHANES, Lanphear 2005, Parsons 2001, OEHHA 2007, EPA IEUBK source code) rather than on novel measurement procedure.

Implications

• Certification (HMTc): This source establishes the U.S. federal regulatory ceiling and the staff-derived public-health-protection methodology for any children’s-product category for which a §101(b) functional-purpose exception from the CPSIA 100 ppm substrate-lead content limit might be petitioned. The binding floor for HMTc certification of US-marketed children’s products is the 100 ppm substrate limit codified by CPSIA §101(a); any HMTc threshold meeting that 100 ppm value is appropriately tagged regulatory-alignment under Part 19 rationale conventions and any HMTc threshold set below 100 ppm should be tagged precautionary with the rationale documented. The staff-derived 2.2 µg/day daily-exposure ceiling (and the 0.8 µg/dL BLL-increase ceiling) are CPSC’s operational definitions of “no measurable adverse effect on public health or safety” for the §101(b) exception decision, not direct content-limit floors — they are exposure-based, not concentration-based, and are decisive at the point where an exception petition is being evaluated, not at the point of routine certification. The staff acknowledgement (p. 9, p. 12) that the de minimus phrasing in OEHHA (2007) and the “no measurable adverse effect” phrasing in CPSIA §101(b)(1)(A)(iii) are likely not coincidental is relevant background for any HMTc rationale that aligns its lead thresholds to a child-specific de minimus framework rather than to a feasibility-driven or precautionary one.
• Courses: Useful as a worked example of how a federal agency derives a quantitative health-protection criterion from published biokinetic models, interlaboratory measurement-precision studies, and dose-response meta-analyses — i.e., how “no measurable adverse effect” gets operationalised when the statute requires a measurable-effect threshold but provides no number. The peer-review appendix is a transparent record of the reviewer–staff disagreements (population-vs-individual framing, non-linearity of the low-BLL dose-response, sensitivity-subgroup protection) and is instructive for QA and regulatory-affairs students learning how peer-review feedback gets integrated into a final staff position.
• App: Not directly relevant to the consumer-app contamination_profile ingestion path. The CPSIA §101(b) statutory scope applies to product substrate and component-part total-lead content, not to food contamination, and the 2.2 µg/day exposure threshold is a regulatory decision criterion for product petitions rather than a per-day intake guideline for individual consumers. The CDC NHANES reference BLL statistics (median 1.4 µg/dL, 95th percentile 4.1 µg/dL for U.S. children ages 1–5) are appropriate context for any future app surface that shows population-level BLL benchmarks alongside food-derived lead-exposure estimates.

Wiki pages this source may touch

• lead
• toys-substrate-materials
• toys-painted
• children-personal-care

Verification notes

• Authorship and date. The cover and §I “Introduction” identify this as a Staff Report dated November 2012 of the U.S. Consumer Product Safety Commission, bearing the standard CPSC staff caveat. No named individual author is on the cover; institutional authorship is recorded as U.S. Consumer Product Safety Commission staff. The cite-key cpsc2012-cpsia-101b-functional-purpose-exception reflects the institutional author, the publication year, and the specific statutory subject (§101(b) functional-purpose exception). The peer-review appendix (Appendix B) establishes the document’s drafting timeline: draft circulated for external review in January 2012, reviewer comments received March 2012, final report November 2012.
• Filename vs. document date. The PDF filename 18_Products_Covered_2011.pdf references the 2011-08-14 effective date of the 100 ppm CPSIA §101(a) substrate limit (the date from which products are “covered” by the 100 ppm cap and thus the regulatory backdrop against which the §101(b) functional-purpose exception is evaluated), not the publication year of the report itself, which is unambiguously November 2012 per the cover and §I. The raw_handle: MFK_18-products-covered-2011 preserves the Kimi-pipeline filename verbatim without re-asserting a 2011 publication date; the year: 2012 field is the actual publication year.
• Source-tier rationale. evidence_tier: A: per Part 13, the A tier covers agency reports and agency guidance documents. This is a CPSC staff regulatory-methodology report that derives an operational interpretation of the CPSIA §101(b)(1)(A)(iii) “no measurable adverse effect” criterion, with a published external scientific peer review by five reviewers and a documented comment-response cycle (Appendix B). The staff caveat that the report “has not been reviewed or approved by, and may not necessarily reflect the views of, the Commission” partially qualifies the institutional weight, but the methodology and the synthesised inputs (CDC NHANES, Lanphear 2005, Parsons 2001, OEHHA 2007, EPA IEUBK, EPA 2008 NAAQS) are agency-and-peer-reviewed-of-record A-tier sources. Treated as A-tier in the corpus pattern for CPSC staff regulatory documents (cf. hatlelid2009-cpsc-cpsia-lead-childrens-products).
• No primary measurements. sample_n: null, matrices: [], ingredients: [] are correct — the report has no field sampling, no analytical chemistry, and no primary measurement of lead in any matrix. It is a methodology-derivation document built from published biokinetic-modelling and meta-analysis inputs. The numerical quantities reported in Key numbers are (i) statutory ppm limits, (ii) BLL summary statistics published by CDC NHANES, (iii) BLL-reference-material certified means and between-laboratory standard deviations published by Parsons et al. (2001), (iv) BLL–IQ regression coefficients and confidence intervals published by Lanphear et al. (2005), and (v) IEUBK biokinetic-model outputs computed by CPSC staff at named default inputs. No primary-data contamination_profile block should be derived from this source.
• products: field. Three product slugs are populated: toys-substrate-materials (the CPSIA §101(a) 100 ppm substrate limit applies directly to toy substrate materials and is the limit that §101(b) functional-purpose exceptions are from); toys-painted (the same children’s-products regulatory regime; the report cross-references the CPSIA Section 101 lead-paint provisions and the staff document is part of the same regulatory family as the Hatlelid 2009 deck and the CFA 2012 fact sheet, which both also route to toys-painted); and children-personal-care (the umbrella slug for children’s products intended for children 12 and under, which is the CPSIA statutory scope). Bicycles, motor sports equipment, and brass parts on a tractor toy are named on p. 13 as specific exception-petition precedents but none have current taxonomy slugs; the routing therefore is held to the slugs the source most directly addresses under the umbrella children’s-products framing.
• matrices: [] is correct: this is a regulatory-derivation document, not a measurement study; there is no analytical matrix in which lead was measured.
• ingredients: [] is correct: ingredients are not the relevant taxonomy axis for a children’s-products substrate-lead regulation report. CPSIA §101 regulates total-lead content in product substrate and surface coatings, not lead in food ingredients.
• jurisdictions: [US] is correct: CPSIA, the Public Law 112-28 amendment, 16 CFR, 42 CFR §493.937, and the Federal Register notices cited are U.S. federal law and rulemaking.
• Brand-firewall (Part 12). The report names no commercial brands. No brand-firewall concern arises.
• Wiki/HMTc firewall (Part 2). The report makes no claims about HMTc certification thresholds; it derives a federal regulatory-decision criterion (the 2.2 µg/day daily-exposure ceiling and the 0.8 µg/dL BLL-increase ceiling) for §101(b) exception petitions. The Implications section above flags that the 100 ppm CPSIA substrate limit is the federal regulatory floor that any HMTc children’s-products certification must at minimum meet and that tighter HMTc thresholds should be labelled with the Part 19 rationale tags; this is a procedural pointer to the threshold-setting workflow, not an HMTc threshold proposal.
• Speciation flag. Not applicable: lead is reported in this document as total-lead content (ppm in product substrate) and as total lead in blood (µg/dL BLL), without speciation. Methylated lead species (e.g., tetraethyl-lead) are not in the regulatory scope of CPSIA §101.
• Unit handling. Two unit families appear: (i) product-substrate concentration in ppm (100, 300, 600 ppm) and (ii) blood-lead level in µg/dL. The IQ-loss arithmetic preserves the source’s reporting (IQ points; BLL coefficient in ln(µg/dL) × IQ points). No silent conversion is applied; the 0.009 % / 90 ppm dried-paint-film equivalence familiar from hatlelid2009-cpsc-cpsia-lead-childrens-products is not invoked because this 2012 staff report addresses the §101(a) 100 ppm substrate limit and the §101(b) exception, not the separately-codified 16 CFR Part 1303 paint-coating rule.
• Statistic-type. The principal numerical outputs derived in the report are (a) a between-laboratory standard deviation (Parsons 2001 SD = 0.4 µg/dL at the 5.9 µg/dL reference sample), (b) a geometric mean and 95th percentile BLL from IEUBK (geometric mean 2.730 µg/dL; 95th percentile 5.915 µg/dL at default inputs), and (c) a regression-coefficient confidence interval (Lanphear 2005 coefficient −2.7 with 95 % CI −3.74 to −1.66 for the ln(BLL) → IQ model). All three statistic types are reported with the source’s expression preserved.
• Censoring / detection-limit handling. Not applicable: no primary measurements.
• External peer review (Appendix B). The report records that draft text was circulated to five external scientific reviewers in January 2012 and that staff revised the draft in response to comments received in March 2012. The appendix tabulates 26 numbered comments with staff responses, including several substantive disagreements: reviewer 2.3.4 contested staff’s interpretation that exceptions would not affect large-population BLL; reviewers 2.1.3 and 2.2.3 pressed for clearer population-vs-individual framing of IQ effects; reviewer 2.4.2 argued for de minimus terminology rather than “negligible/insignificant”; reviewers 2.2.3 and 2.3.3 contested the report’s framing that small affected-subgroup IQ effects do not constitute “measurable adverse effect.” Staff responses range from “revised text” / “clarified text” acknowledgements to explicit non-concurrence on framing. The peer-review record is consistent with this being a contested-but-final staff position rather than a Commission rulemaking.
• License. public-reference-only: CPSC staff reports published on CPSC platforms are U.S. government works in the public domain (17 USC §105), so re-hosting and quotation are unrestricted under U.S. law; the conservative public-reference-only label matches the corpus pattern for U.S. agency regulatory summary documents (cf. cfa2012-cpsia-lead-fact-sheet, hatlelid2009-cpsc-cpsia-lead-childrens-products).
• Audit subagent application (2026-06-01). A fresh-context audit subagent (general-purpose, Claude Opus 4.7) returned a PROMOTE verdict with two ⚠️ concerns and no ❌ definite-error findings. (a) Concern 1 — the “1.4 % / 4.4 %” prevalence-of-BLL≥10 µg/dL pair was originally written as if attributed to CDC 2012; verified against the PDF p. 3, the source attributes that historical pair to CDC 2009 (the median 1.4 µg/dL and 95th percentile 4.1 µg/dL distribution statistics are the CDC 2012 attributions). Corrected — the prevalence pair is now explicitly cited to CDC 2009 in the Key numbers bullet, while the distribution statistics remain cited to CDC 2012. (b) Concern 2 — slug-fit of products/toys-painted is a curatorial judgment, not a fidelity question: the audit observed that the 2012 staff report addresses CPSIA §101(a) total-substrate-lead, not the separately-codified 16 CFR Part 1303 paint-coating rule. The routing here matches the corpus pattern for the CPSC family of regulatory documents (cf. hatlelid2009-cpsc-cpsia-lead-childrens-products, cpsc1997-pvc-children-products) and is held pending Step 0 Lock of the toy-product taxonomy rows. Left as-is.
• Related corpus pages. hatlelid2009-cpsc-cpsia-lead-childrens-products (a 12/17/2009 14-slide CPSC staff presentation on the same CPSIA §101 regulatory regime, predating the Public Law 112-28 amendment to §101(b)) is the closest existing companion source; that earlier deck described the unamended §101(b) exclusion framework (no-absorption and no-other-adverse-impact criteria), while this 2012 staff report develops the public-health-protection methodology required by the amended §101(b) (functional-purpose exception with the “no measurable adverse effect” / “no measurable increase in BLL” criteria). cfa2012-cpsia-lead-fact-sheet is a contemporaneous consumer-advocacy summary of the same regulatory regime. johnson2012-cpsc-astm-f963-status is a CPSC-adjacent reference for toy-safety standards (different regulatory hook). No CPSIA-§101-specific regulation page yet exists in wiki/regulations/; the same observation appears in the hatlelid2009-cpsc-cpsia-lead-childrens-products and cfa2012-cpsia-lead-fact-sheet verification notes. Per Part 10 and the manual-fetch skill, a regulation-page proposal is a Karen-curated step, not an ingest-time auto-creation.

Page history

The five most recent substantive edits to this page. The full version history lives in git; when DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.